SinoMab BioScience Limited on 24 July 2026 approved the issuance of 18.03 million share options to two key personnel under its 2022 Share Option Scheme, which was adopted in October 2022 and amended in June 2024.

The options were allocated as follows: • Executive Director and Chief Operating Officer Ms. Fang Liang received 11.09 million options. • One non-director employee was granted 6.93 million options.

Each option entitles the holder to subscribe for one ordinary share of SinoMab at an exercise price of HK$1.20 per share, equal to the Grant Date closing price and above the HK$1.152 average of the preceding five trading days. The options are exercisable from their respective vesting commencement dates until 23 July 2036.

Vesting terms are performance-linked. For Ms. Liang, 5.55 million options vest on 24 July 2027, followed by eight equal monthly tranches of 0.69 million options from August 2027 to March 2028, contingent on annual performance evaluations. The employee’s award vests in a similar pattern, with 2.08 million options on 24 July 2027 and 1.73 million options spread over 12 monthly instalments to July 2028, plus two milestone-based tranches totalling 2.77 million options that cannot vest before 24 July 2027.

The remuneration committee determined that no claw-back clause was necessary, citing existing lapse and cancellation provisions within the scheme. No financial assistance will be provided to the grantees for share subscription.

Post-grant, 34.02 million shares remain available for future option issuances under the scheme mandate, while the service-provider sub-limit is fully utilised. The independent non-executive directors reviewed and approved the grant in accordance with Hong Kong Listing Rule 17.04(1); Ms. Liang abstained from voting on her own award. The company confirmed that neither grantee breaches the 1% individual option limit in the preceding 12-month period.